Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other Routine +

Grey Matters Health Signs LOI with Catalyst MedTech for 200 Brain PET Scans for Alzheimer's Clinical Trial at 2nd NovaScan Location Planned for Tampa

Grey Matters Health Signs LOI for Tampa Trial, Yet Dilution and Timeline Risks Persist

By The Northwire Desk — AI Analysis May 20, 2026 · 07:00 GREY · 0.4 Grey Matters Health Inc.
Executive Summary
  • Grey Matters Health Inc. signed a non-binding Letter of Intent (LOI) with Catalyst MedTech on May 20, 2026.
  • The agreement covers a minimum of 200 brain PET scans for an Alzheimer’s Disease clinical trial at the planned Tampa location.
  • A definitive services agreement is intended to be signed within 60 days of the LOI date.
  • The company announced a private placement on April 22, 2026, raising CAD $1,000,000 at $0.40 per unit.
  • Proceeds from the financing are designated for advancing the Alzheimer’s program and opening the first U.S. neuroimaging clinic in Davie (Q3 2026) and Tampa (Q4 2026).
  • The clinics will utilize the FDA-cleared CareMiBrain system to reduce radiation exposure by 25%.
Material Impact
  • The LOI represents validation of the business model but is non-binding, creating execution risk regarding revenue recognition.
  • Revenue from this agreement is not immediate; it depends on clinic openings scheduled for late 2026 (Q3/Q4).
  • The April private placement diluted shareholders at $0.40 per unit, while current trading prices hover near $0.38, indicating market skepticism or continued selling pressure post-financing.
  • No material change to the cash runway is evident; the company remains in a pre-revenue development phase with significant capital needs for clinic build-out.
  • The news does not alter the fundamental risk profile regarding dilution or execution timelines significantly enough to be classified as Material Positive.
GREY · Price
Company Overview
  • Grey Matters Health Inc. operates a network of private U.S. neuroimaging clinics specializing in neurological conditions including Alzheimer’s Disease, Epilepsy, Parkinson’s, Multiple Sclerosis, and brain cancers.
  • Flagship Project: NovaScan Neuroimaging Clinics™ utilizing the CareMiBrain system.
  • Development Status: Inaugural Davie clinic planned for Q3 2026; second Tampa location planned for end of Q4 2026.
  • Technology Focus: Standalone diagnostic brain PET scanner designed to reduce radiation exposure and improve patient comfort via an open, upright imaging environment.
Read the original news release →

More from Grey Matters Health Inc.

Jun 05, 2026 · 16:01

Grey Matters Health Secures $500K Tranche as Florida Neuroimaging Clinics Edge Closer to Opening

Financings May 25, 2026 · 07:00

Grey Matters Amends Warrant Terms to Secure Financing as Clinic Expansion Nears; Stock Holds Near Issue Price

Financings Apr 22, 2026 · 07:00

Grey Matters Health Raises Capital at Discount to Fund US Clinic Expansion Amidst Dilution Concerns

Financings